Suppr超能文献

相似文献

2
Evaluation of the nonparametric estimation method in NONMEM VI.
Eur J Pharm Sci. 2009 Apr 11;37(1):27-35. doi: 10.1016/j.ejps.2008.12.014. Epub 2008 Dec 30.
3
Estimating bias in population parameters for some models for repeated measures ordinal data using NONMEM and NLMIXED.
J Pharmacokinet Pharmacodyn. 2004 Aug;31(4):299-320. doi: 10.1023/b:jopa.0000042738.06821.61.
4
Pharmacodynamic parameter estimation: population size versus number of samples.
AAPS J. 2005 Oct 5;7(2):46. doi: 10.1208/aapsj070246.
7
Nearly unbiased estimators for the three-parameter Weibull distribution with greater efficiency than the iterative likelihood method.
Br J Math Stat Psychol. 2009 Feb;62(Pt 1):167-91. doi: 10.1348/000711007X270843. Epub 2008 Jan 3.
8
Endogeneity bias in the absence of unobserved heterogeneity.
Ann Epidemiol. 2004 Sep;14(8):561-5. doi: 10.1016/j.annepidem.2003.09.020.
10
Estimation of pharmacokinetic parameters from non-compartmental variables using Microsoft Excel.
Comput Biol Med. 2005 Jun;35(5):389-403. doi: 10.1016/j.compbiomed.2004.02.008.

引用本文的文献

2
Optimised protocol design for the screening of analgesic compounds in neuropathic pain.
J Pharmacokinet Pharmacodyn. 2012 Dec;39(6):661-71. doi: 10.1007/s10928-012-9277-x. Epub 2012 Nov 30.
3
Estimating bias in population parameters for some models for repeated measures ordinal data using NONMEM and NLMIXED.
J Pharmacokinet Pharmacodyn. 2004 Aug;31(4):299-320. doi: 10.1023/b:jopa.0000042738.06821.61.

本文引用的文献

1
A two-part mixture model for longitudinal adverse event severity data.
J Pharmacokinet Pharmacodyn. 2003 Oct;30(5):315-36. doi: 10.1023/b:jopa.0000008157.26321.3c.
2
Use of prior information to stabilize a population data analysis.
J Pharmacokinet Pharmacodyn. 2002 Dec;29(5-6):473-505. doi: 10.1023/a:1022972420004.
3
Commentary on significance levels for covariate effects in NONMEM.
J Pharmacokinet Pharmacodyn. 2002 Aug;29(4):403-10; discussion 411-2. doi: 10.1023/a:1020909324909.
4
Population pharmacokinetic and adverse event analysis of topotecan in patients with solid tumors.
Clin Pharmacol Ther. 2002 May;71(5):334-48. doi: 10.1067/mcp.2002.123553.
5
Nonlinearity detection: advantages of nonlinear mixed-effects modeling.
AAPS PharmSci. 2000;2(3):E32. doi: 10.1208/ps020332.
6
The need for mixed-effects modeling with population dichotomous data.
J Pharmacokinet Pharmacodyn. 2001 Aug;28(4):389-412. doi: 10.1023/a:1011586814601.
7
Assessment of actual significance levels for covariate effects in NONMEM.
J Pharmacokinet Pharmacodyn. 2001 Jun;28(3):231-52. doi: 10.1023/a:1011527125570.
8
Evaluating pharmacokinetic/pharmacodynamic models using the posterior predictive check.
J Pharmacokinet Pharmacodyn. 2001 Apr;28(2):171-92. doi: 10.1023/a:1011555016423.
10
A Markov mixed effect regression model for drug compliance.
Stat Med. 1998 Oct 30;17(20):2313-33. doi: 10.1002/(sici)1097-0258(19981030)17:20<2313::aid-sim935>3.0.co;2-v.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验